Characterization of vascular reactivity in dorsal hand veins after oral rosiglitazone treatment in healthy subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 46, Issue 1, 2008, Pages 30-39

  Schindler, C ^a   Ferrario, C M ^b   Jatzke, C ^a   Ahner, K ^a   Brosnihan, K B ^b   Bramlage, P ^a   Maywald, U ^a   Oertel, R ^a   Boecking, W ^a   Kirch, W ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II; Endothelium; Rosiglitazone; Smooth muscle; Vascular effects; Veins

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN[1-7]; GLYCERYL TRINITRATE; HISTAMINE; INSULIN; PHENYLEPHRINE; PLACEBO; RENIN; ROSIGLITAZONE;

ADULT; APPETITE DISORDER; ARTERY COMPLIANCE; ARTICLE; BLOOD FLOW VELOCITY; BLOOD VESSEL REACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FLATULENCE; HUMAN; HUMAN EXPERIMENT; HUNGER; MALE; MORNING DOSAGE; NORMAL HUMAN; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASODILATATION; VEIN BLOOD FLOW; VEIN COMPLIANCE; VEIN TONE; WEAKNESS;

EID: 38349030367     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP46030     Document Type: Article

References (53)

1. Aellig WH. A new technique for recording compliance of human hand veins. 1981. Br J Clin Pharmacol. 2004; 58: S768-774; discussion S775-777.
2. Alradi AO, Carruthers SG. Evaluation and application of the linear variable differential transformer technique for the assessment of human dorsal hand vein alpha-receptor activity. Clin Pharmacol Ther. 1985; 38: 495-502.
3. Baron AD. Insulin and the vasculature - old actors, new roles. J Investig Med. 1996; 44: 406-412.
4. Bell DS. Unilateral edema due to a thiazolidinedione. Diabetes Care. 2003; 26: 2700.
5. Chen K et al. Angiotensin II regulation of collagen type I expression in cardiac fibroblasts: modulation by PPAR-gamma ligand pioglitazone. Hypertension. 2004; 44: 655-661.
6. Dormandy JA et al. Secondary prevention of macro-vascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomised controlled trial. Lancet. 2005; 366: 1279-1289.
7. Eckberg DL et al. Baroreflex control of plasma norepinephrine and heart period in healthy subjects and diabetic patients. J Clin Invest. 1986; 78: 366-374.
8. Eichler HG et al. Responsiveness of superficial hand veins to alpha-adrenoceptor agonists in insulin-dependent diabetic patients. Clin Sci (Lond). 1992; 82: 163-168.
9. Esposito K et al. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care. 2006; 29: 1071-1076.
10. Eto K et al. Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle. Eur J Pharmacol. 2001; 423: 1-7.
11. Feldman RD, Schmidt ND. Quinapril treatment enhances vascular sensitivity to insulin. J Hypertens. 2001; 19: 113-118.
12. Ford GA et al. Responsiveness of peripheral veins to vasodilators and the effect of nifedipine on alpha-adrenergic responsiveness in hypertension. Clin Pharmacol Ther. 1991; 50: 192-198.
13. Fritsche L et al. Treating type 2 diabetes in renal insufficiency: the role of pioglitazone. Int J Clin Pharmacol Ther. 2003; 41: 488-491.
14. Gaillard V et al. Pioglitazone improves aortic wall elasticity in a rat model of elastocalcinotic arteriosclerosis. Hypertension. 2005; 46: 372-379.
15. Graf K et al. Troglitazone inhibits angiotensin II-induced DNA synthesis and migration in vascular smooth muscle cells. FEBS Lett. 1997; 400: 119-121.
16. Harada K et al. Vasoconstricting effect of angiotensin II in human hand veins: influence of aging, diabetes mellitus and hypertension. Hypertens Res. 2002; 25: 683-638.
17. Hetzel J et al. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol. 2005; 25: 1804-1809.
18. Kahn SE et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355: 2427-2743.
19. Kotchen TA et al. Effect of pioglitazone on vascular reactivity in vivo and in vitro. Am J Physiol. 1996; 270: R660-666.
20. Law RE et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest. 1996; 98: 1897-1905.
21. Lembo G et al. Insulin blunts sympathetic vasoconstriction through the alpha 2-adrenergic pathway in humans. Hypertension. 1994; 24: 429-438.
22. Marx N et al. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res. 1998; 83: 1097-1103.
23. Marx N et al. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res. 2004; 94: 1168-1178.
24. Matsushita K et al. Local renin angiotensin expression regulates human mesenchymal stem cell differentiation to adipocytes. Hypertension. 2006; 48: 1095-1102.
25. Millasseau SC et al. Evaluation of carotid-femoral pulse wave velocity: influence of timing algorithm and heart rate. Hypertension. 2005; 45: 222-226.
26. Murakami T et al. Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus. Am J Cardiol. 1999; 84: 92-94, A8.
27. Nakamoto H et al. Angiotensin-(1-7) and nitric oxide interaction in renovascular hypertension. Hypertension. 1995; 25: 796-802.
28. Nakamura Y et al. Inhibitory action of insulin-sensitizing agents on calcium channels in smooth muscle cells from resistance arteries of guinea-pig. Br J Pharmacol. 1998; 123: 675-682.
29. Natali A et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care. 2004; 27: 1349-1357.
30. Nesto RW et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation. 2003; 108: 2941-2948.
31. Neubauer B, Christensen NJ. Norepinephrine, epinephrine, and dopamine contents of the cardiovascular system in long-term diabetics. Diabetes. 1976; 25: 6-10.
32. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med; 2007.
33. Rennings AJ et al. Fluid retention and vascular effects of rosiglitazone in obese, insulin-resistant, nondiabetic subjects. Diabetes Care. 2006; 29: 581-587.
34. Ryan MJ et al. PPAR (gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension. 2004; 43: 661-666.
35. Sader MA, Celermajer DS. Endothelial function, vascular reactivity and gender differences in the cardiovascular system. Cardiovasc Res. 2002; 53: 597-604.
36. Schindler C. The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis? Ther Adv Cardiovasc Dis. 2007; 1: 7-26.
37. Schindler C et al. Reproducibility of dorsal hand vein responses to phenylephrine and prostaglandin F2 alpha using the dorsal hand vein compliance method. J Clin Pharmacol. 2003; 43: 228-236.
38. Schindler C et al. Mechanisms of beta-adrenergic receptor-mediated venodilation in humans. Clin Pharmacol Ther. 2004; 75: 49-59.
39. Schindler C et al. Comparison of inhibitory effects of irbesartan and atorvastatin treatment on the renin angiotensin system (RAS) in veins: a randomized double-blind crossover trial in healthy subjects. J Clin Pharmacol. 2007; 47: 112-120.
40. Schupp M et al. Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites. Hypertension. 2006; 47: 586-589.
41. Sourij H et al. Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. Diabetes Care. 2006; 29: 1039-1045.
42. Sowers JR et al. Mechanisms of hypertension in diabetes. Am J Hypertens. 1991; 4: 177-182.
43. Staels B et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPAR-gamma activators. Nature. 1998; 393: 790-793.
44. Tack CJ et al. Regional hyperinsulinemia induces vasodilation but does not modulate adrenergic responsiveness in humans. J Cardiovasc Pharmacol. 1996a; 28: 245-251.
45. Tack CJ et al. Direct vasodilator effects of physiological hyperinsulin-aemia in human skeletal muscle. Eur J Clin Invest. 1996b; 26: 772-778.
46. Takeda K et al. Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation. 2000; 102: 1834-1839.
47. Tooke JE et al. The insulin sensitiser pioglitazone does not influence skin microcirculatory function in patients with type 2 diabetes treated with insulin. Diabetologia. 2006; 49: 1064-1070.
48. Wang TD et al. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol. 2004; 93: 362-365.
49. Wong FS et al. Effect of insulin on the venoconstrictive response to norepinephrine in normal human subjects: the influence of sodium status. Am J Hypertens. 1994; 7: 1097-1104.
50. Xin X et al. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem. 1999; 274: 9116-9121.
51. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004; 351: 1106-1118.
52. Zeng G et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation. 2000; 101: 1539-1545.
53. Zhang F et al. Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension. 1994; 24: 170-175.